| Title |
Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, October 2013
|
| DOI | 10.1007/s00228-013-1600-y |
| Pubmed ID | |
| Authors |
G. Désaméricq, F. Schurhoff, A. Meary, A. Szöke, I. Macquin-Mavier, A. C. Bachoud-Lévi, P. Maison |
| Abstract |
Most schizophrenic patients have mild to moderate cognitive impairment in the early stages of schizophrenia. The aim was to compare the long-term effects of various antipsychotic drugs on overall cognition and on specific cognitive domains in patients with schizophrenia or related disorders. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 21% |
| Japan | 2 | 14% |
| United States | 1 | 7% |
| Italy | 1 | 7% |
| Unknown | 7 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 57% |
| Scientists | 3 | 21% |
| Practitioners (doctors, other healthcare professionals) | 3 | 21% |
Mendeley readers
The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 1% |
| Sweden | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 161 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 30 | 18% |
| Student > Ph. D. Student | 20 | 12% |
| Student > Master | 18 | 11% |
| Student > Bachelor | 17 | 10% |
| Student > Postgraduate | 15 | 9% |
| Other | 36 | 22% |
| Unknown | 29 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 28% |
| Psychology | 29 | 18% |
| Neuroscience | 23 | 14% |
| Agricultural and Biological Sciences | 9 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Other | 16 | 10% |
| Unknown | 36 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 September 2020.
All research outputs
#2,535,244
of 25,837,817 outputs
Outputs from European Journal of Clinical Pharmacology
#184
of 2,805 outputs
Outputs of similar age
#22,720
of 227,968 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#3
of 23 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,805 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 227,968 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.